Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology

Journal of Clinical Pharmacology

Volumn 55, Issue 10, 2015, Pages 1101-1108

  Polepally, Akshanth R ^a   Remmel, Rory P ^a   Brundage, Richard C ^a   Leppik, Ilo E ^a,b   Rarick, John O ^a   Ramsay, R Eugene ^c,d   Birnbaum, Angela K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Ochsner Baptist Medical Center   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

elderly; extended release; immediate release; lamotrigine; stable isotope

Indexed keywords

LAMOTRIGINE; ANTICONVULSIVE AGENT; CARBON; DELAYED RELEASE FORMULATION; NITROGEN; TRIAZINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; EPILEPSY; EXTENDED RELEASE FORMULATION; FEMALE; GERIATRIC DISORDER; HUMAN; IMMEDIATE RELEASE FORMULATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION; VERY ELDERLY; VOLUME OF DISTRIBUTION; ADMINISTRATION AND DOSAGE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBON ISOTOPES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROGEN ISOTOPES; TRIAZINES;

EID: 84940892669     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.522     Document Type: Article

References (30)

1. Hammerlein A, Derendorf H, Lowenthal DT., Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998; 35 (1): 49-64.
2. McLean AJ, Le Couteur DG., Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004; 56 (2): 163-184.
3. Gidal BE., Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res. 2006; 68 (Suppl 1): S65-S69.
4. Ramsay RE, Cloyd JC, Kelly KM, Leppik IE, Perucca E., The Neurobiology of Epilepsy and Aging. San Diego: Academic Press; 2007.
5. Werz MA., Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. Ther Clin Risk Manag. 2008; 4 (5): 1035-1046.
6. Lamictal® XR™ (package insert). Glaxo-SmithKline, Research Triangle Park. 2011.
7. Tompson DJ, Ali I, Oliver-Willwong R, et al., Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia. 2008; 49 (3): 410-417.
8. Baillie TA., The use of stable isotopes in pharmacological research. Pharmacol Rev 1981; 33 (2): 81-132.
9. Conway JM, Birnbaum AK, Leppik IE, et al., Safety of an intravenous formulation of lamotrigine. Seizure. 2014; 23 (5): 390-392.
10. Bioanalytical method validation. US Food and Drug Administration, Rockville. 2001.
11. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; March 2003.
12. Lamictal® (package insert). Glaxo-SmithKline, Research Triangle Park. 2011.
13. Leppik IE, Hovinga CA., Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia. 2012; 54 (1): 28-35.
14. Weintraub D, Buchsbaum R, Resor SR, Jr., et al., Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005; 62 (9): 1432-1436.
15. Brzakovic BB, Vezmar Kovacevic SD, Vucicevic KM, et al., Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. J Clin Pharm Ther. 2012; 37 (6): 693-697.
16. Argikar UA, Remmel RP,. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009; 39 (5): 355-363.
17. Posner J, Holdich TA, Crome P,. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med. 1991; 1: 121-128.
18. Hussein Z, Posner J,. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997; 43 (5): 457-465.
19. Chan V, Morris RG, Ilett KF, et al., Population pharmacokinetics of lamotrigine. Ther Drug Monit. 2001; 23 (6): 630-635.
20. Punyawudho B, Ramsay RE, Macias FM, et al., Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol. 2008; 48: 455-463.
21. Murphy PJ, Sullivan HR., Stable isotopes in pharmacokinetic studies. Annu Rev Pharmacol Toxicol. 1980; 20: 609-621.
22. Clark AM, Kriel RL, Leppik IE, et al., Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia. 2013; 54 (6): 1099-1105.
23. Marino SE, Birnbaum AK, Leppik IE, et al., Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012; 91 (3): 483-488.
24. Ahn JE, Cloyd JC, Brundage RC, et al., Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology. 2008; 71 (1): 38-43.
25. Hoffmann F, von Unruh GE, Jancik BC,. Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. Eur J Clin Pharmacol. 1981; 19 (5): 383-385.
26. von Unruh GE, Jancik BC, Hoffman F,. Determination of valproic acid kinetics in patients during maintenance therapy using a tetradeuterated form of the drug. Biomed Mass Spectrom. 1980; 7 (4): 164-167.
27. Rowland A, Elliot DJ, Williams JA, et al., In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006; 34 (6): 1055-1062.
28. Cohen AF, Land GS, Breimer DD, et al., Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987; 42 (5): 535-541.
29. Arif H, Svoronos A, Resor SR, Jr., et al., The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia. 52 (10): 1905-1913.
30. Yuen WC, Peck AW,. Lamotrigine Pharmacokinetics: oral and i.v.infusion in man. Br J Clin Pharmacol. 1988; 26 (proceedings): 242.